Response to therapy in myasthenia gravis with anti-MuSK antibodies

Annals of the New York Academy of Sciences

Volumn 1132, Issue , 2008, Pages 76-83

  Evoli, Amelia ^a   Bianchi, Maria R ^a   Riso, Raffaella ^a   Minicuci, Giacomo M ^a   Batocchi, Anna P ^a   Servidei, Serenella ^a   Scuderi, Flavia ^a   Bartoccioni, Emanuela ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anti MuSK antibodies; Cholinesterase inhibitors; Corticosteroids; Immunosuppressive therapy; MuSK positive myasthenia gravis; Plasma exchange; Thymectomy

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MUSCLE SPECIFIC TYROSINE KINASE MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB;

ADOLESCENT; ADULT; AGED; CHILD; CLINICAL FEATURE; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; FASCICULATION; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE CRAMP; MYASTHENIA GRAVIS; PLASMAPHERESIS; SALIVATION; SEX DIFFERENCE; SIDE EFFECT; TREATMENT RESPONSE;

EID: 45249105334     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1405.012     Document Type: Conference Paper

References (47)

1. Hoch, W. et al. 2001. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7 : 365 368.
2. Vincent, A. & M.I. Leite. 2005. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr. Opin. Neurol. 18 : 519 525.
3. Caress, J.B., C.H. Hunt & S.D. Batish. 2005. Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch. Neurol. 62 : 1002 1003.
4. Zhou, L. et al. 2004. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 30 : 55 60.
5. Sanders, D.B. et al. 2003. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60 : 1978 1980.
6. Evoli, A. et al. 2003. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126 : 2304 2311.
7. Keesey, J.C. 2004. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29 : 484 505.
8. Richman, D.P. & M.A. Agius. 2003. Treatment of autoimmune myasthenia gravis. Neurology 61 : 1652 1661.
9. Vincent, A. 2002. Unraveling the pathogenesis of myasthenia gravis. Nat. Rev. Immunol. 2 : 797 804.
10. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Jaretzki, A. et al. 2000. Myasthenia gravis: recommendations for clinical research standards. Neurology 55 : 16 23.
11. Lavrnic, D. et al. 2005. The features of myasthenia gravis with autoantibodies to MuSK. J. Neurol. Neurosurg. Psychiatry 76 : 1099 1102.
12. Lee, J.Y. et al. 2006. MuSK antibody-positive, seronegative myasthenia gravis in Korea. J. Clin. Neurosci. 13 : 353 355.
13. Farrugia, M.E. et al. 2006. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 129 : 1481 1492.
14. Sanders, D.B., J.M. Massey & V.C. Juel. 2007. MuSK antibody positive myasthenia gravis: response to treatment in 31 patients [abstract]. Neurology 68 (Suppl 1 A299.
15. Oosterhuis, H.J.G.H. 1988. Long-term effects of treatment in 374 patients with myasthenia gravis. Monogr. Allergy 25 : 75 85.
16. Mantegazza, R. et al. 1990. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J. Neurol. 237 : 339 344.
17. Donaldson, D. H. et al. 1990. The relationship of age to outcome in myasthenia gravis. Neurology 40 : 786 790.
18. Beekman, R. et al. 1997. Myasthenia gravis: diagnosis d follow-up of 100 consecutive patients. J. Neurol. 244 : 112 118.
19. Robertson, N.P., J. Deans & D.A.S. Compston. 1998. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J. Neurol. Neurosurg. Psychiatry 65 : 492 496.
20. Mantegazza, R. et al. 2003. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann. N.Y. Acad. Sci. 998 : 413 423.
21. Kawaguchi N. et al. 2004. Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999-2000. J. Neurol. Sci. 224 : 43 47.
22. Tsinzerling, N. et al. 2007. Myasthenia gravis: A long-term follow-up study of Swedish patients with special reference to thymic histology. J. Neurol. Neurosurg. Psychiatry 78 : 1109 1112.
23. Hatanaka, Y. et al. 2005. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology 65 : 1508 1509.
24. Rostedt Punga, A. et al. 2006. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve 34 : 111 115.
25. Cartaud, A. et al. 2007. MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction. J. Cell Biol. 165 : 505 515.
26. Chevessier, F. et al. 2004. MUSK, a new target for mutations causing congenital myasthenic syndrome. Hum. Mol. Gen. 13 : 3229 3240.
27. Deymeer, F. et al. 2007. Clinical comparison of anti-MuSK- versus anti-AChR-positive and seronegative myasthenia gravis. Neurology 68 : 609 611.
28. Stickler, D.E. & L.L. Stickler. 2007. Single-fiber electromyography during menstrual exacerbation and ovulatory suppression in MuSK antibody-positive myasthenia gravis. Muscle Nerve 35 : 808 811.
29. Takahashi, H. et al. 2006. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis. J. Neurol. Sci. 247 : 239 241.
30. Murai, H. et al. 2006. Infantile onset myasthenia gravis with MuSK antibodies. Neurology 67 : 174.
31. Ishii, W. et al. 2005. Myasthenia gravis with anti-MuSK antibody, showing progressive muscular atrophy without blepharoptosis. Intern. Med. 44 : 671 672.
32. Lauriola, L. et al. 2005. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 64 : 536 538.
33. Leite, M.I. et al. 2005. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative myasthenia gravis. Ann. Neurol. 57 : 444 448.
34. Bartoccioni, E. et al. 2006. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 67 : 505 507.
35. Saka, E. et al. 2005. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 65 : 782 783.
36. Hain, B. et al. 2006. Successful treatment of MuSK antibody positive myasthenia gravis with rituximab. Muscle Nerve 33 : 575 580.
37. Lin, P. et al. 2006. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve 33 : 433 435.
38. Drachman, D.B. et al. 2003. Treatment of refractory myasthenia: 'rebooting' with high-dose cyclophosphamide. Ann. Neurol. 53 : 29 34.
39. Farrugia, M.E. et al. 2007. Quantitative EMG of facial muscles in myasthenia patients with MuSK antibody. Clin. Neurophysiol. 118 : 269 277.
40. Rostedt Punga, A. et al. 2006. Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin. Neurophysiol. 117 : 1434 1443.
41. Evoli, A. et al. 1996. Clinical heterogeneity of seronegative myasthenia gravis. Neuromusc. Disord. 6 : 155 161.
42. Engel, W.K. & D.E. McFarlin. 1966. Muscle lesions in myasthenia gravis. Ann. N.Y. Acad. Sci. 135 : 68 78.
43. Oosterhuis, H.J.G.H. 1997. Myasthenia Gravis. Groningen Neurological Press. Groningen. Chapter 7 : 173 175.
44. Servidei, S. et al. 2006. Association of myasthenia gravis and mitochondrial myopathy: double trouble or pathogenically correlated diseases? [abstract] Neuromusc. Disord. 16 (Suppl 1 152.
45. Bienveniste, O. et al. 2005. MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo. J. Neuroimmunol. 170 : 41 48.
46. Jha, S. et al. 2006. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J. Neuroimmunol. 175 : 107 117.
47. Xu, K. et al. 2006. Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis. Neuroscience 143 : 655 659.